Work

Tyrosine Kinases as Multifaceted Drug Targets for Therapeutic Intervention in the Treatment of Alzheimer's Disease

Year: 2024
Type: dissertation
Abstract: Alzheimer's Disease (AD) is a neurodegenerative disease of aging for which there currently exists no cure.Clinical symptoms include cognitive impairment, loss of memory, impaired visuospatial and executive skills, and psychological symptoms such as anxiety and depression.The primary pathological hallmarks of AD include neurotoxic aggregations of amyloid-beta and hyperphosphorylated tau as well as rampant neuroinflammation involving activation of microglia, which are believed to synergistically contribute to synaptic dysfunction, neuron death, and accelerated cognitive decline.Disease-modifying therapies targeting these features are being developed aimed at alleviating progression of dementia, but approved drug therapies have demonstrated only modest, temporary, and palliative benefits.One class of enzyme being explored in both preclinical and clinical settings for efficacy in treating neurodegenerative diseases is tyrosine kinases (TKs).Many of these enzymes are upregulated in postmortem brains from AD patients, while recent data has implicated TK activity in AD pathology, suggesting them as therapeutic targets for alleviating pathology.Thus, I hypothesized that pharmacological inhibition of TKs would alleviate pathological features of AD.I first showed that TK inhibition with nilotinib in a human cohort of AD patients is associated with changes to biomarkers known as miRNAs indicative of reduced pathology, including vascular fibrosis, autophagy, and inflammation.Then, using novel small molecule compounds, I was able to demonstrate that tyrosine kinase inhibition is associated with reduced pathological markers in animal models of AD, including peripheral mast cell activation, aggregation of neurotoxic protein, and microglial-
Language: English
Open Access status: green
OpenAlex ID: W6987755242
Cites: 199
Cited by:
Related to: 10